NeoPharm Announces Appointment of Guillermo A. Herrera, Pharmaceutical Industry Executive, as President, Chief Executive Officer and Director

Mr. Herrera spent 24 years at Abbott Laboratories (NYSE:ABT).During his long and distinguished career, he most recently served asSenior Vice President, International Operations and President ofAbbott International. In 2004, Mr. Herrera joined Rosetta PartnersLLC, a biotechnology investment management company, as the Partner andPrincipal in charge of Rosetta's private equity division.

"We are very pleased to have Guillermo Herrera join NeoPharm,"said Frank C. Becker, NeoPharm's Chairman of the Board of Directors."He is an accomplished pharmaceutical industry executive and a provenleader. He brings to NeoPharm a demonstrated track record in drugdevelopment, approval, and commercialization. He is exceptionallyqualified to lead NeoPharm and help to advance the commercializationof the products under development in our drug portfolio." The searchcommittee of the Board of Directors was comprised of directors PaulFreiman, Erick Hanson, and John Kapoor.

"I am enthused about joining NeoPharm," said Guillermo Herrera."The Company has a strong product portfolio. I am particularly excitedabout the Company's lead drug candidates under development:cintredekin besudotox, which is currently in a pivotal Phase IIIclinical trial to confirm its potential to help patients sufferingfrom glioblastoma multiforme, the most aggressive form of braincancer; LEP-ETU, which, as previously announced by the Company, hasbeen determined to be bioequivalent to Taxol(R); and LE-SN38, forwhich the Company expects to begin enrolling patients in a Phase IIstudy for colorectal cancer in the near future. I am looking forwardto working with NeoPharm's board, management team, and employees, aswell as its other constituencies, including business partners andclinical trial investigators, to further advance our product portfolioand achieve both medical and commercial success."

"The Board would also like to thank Ronald G. Eidell for hisaccomplishments as interim President and CEO over the last eightmonths," continued Becker. "We are pleased that Ron will continue toserve as a director of the Company and will rejoin the Audit Committeewhere he will serve as that Committee's financial expert. Ron willwork with Guillermo to help effect a smooth transition ofresponsibilities and to ensure a continuing focus on the Company'songoing programs and initiatives."

About Guillermo A. Herrera

Herrera spent 24 years at Abbot Laboratories (NYSE:ABT), mostrecently serving as Senior Vice President, International Operationsand President of Abbott International. In this role, Mr. Herrera wasaccountable for International Commercial Operations reporting to theChief Operating Officer of the Pharmaceutical Product Group (PPG). Mr.Herrera participated in the development of the long-term PPG strategyand served as a member of the Pharmaceutical Executive Committee. Hewas responsible for Abbott's sales and marketing of pharmaceutical,nutritional and hospital products in markets outside the US. Among hisaccomplishments in this role were the successful launch of Humira(R)(Abbott's monoclonal antibody for rheumatoid arthritis) in Europe, andthe successful completion of the integration of Knoll Pharmaceuticals,a former unit of BASF, into Abbott operations. In 2004, Mr. Herreraleft Abbott and joined Rosetta Partners LLC to serve as the Partnerand Principal in charge of the private equity division. RosettaPartners LLC is a privately-held biotechnology investment managementcompany consisting of two principal funds, a hedge fund focused onbiotech, publicly traded, second/third tier corporations, and aPrivate Equity fund focused in biotechnology start-ups, angel rounds,financing, and venture capital management. Mr. Herrera received a BAin Industrial Economics from the Universidad del Valle, Colombia, andhis MBA from the Kellogg Graduate School of Management at NorthwesternUniversity. Mr. Herrera is on the Board of Directors of the LakeForest Graduate School of Management and ConjuGon, Inc., a privatelyheld biotechnology company.

About NeoPharm, Inc.

NeoPharm, Inc., based in Lake Forest, Illinois, is a publiclytraded biopharmaceutical company dedicated to the research,development and commercialization of new and innovative cancer drugsfor therapeutic applications. The Company has a portfolio of cancercompounds in various stages of development. Additional information canbe obtained by visiting NeoPharm's Website at www.neophrm.com.

Forward Looking Statements - This press release contains"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Actof 1934. The Company has tried to identify such forward-lookingstatements by use of such words as "expects," "intends," "hopes,""anticipates," "believes," "could," "may," "evidences" and"estimates," and other similar expressions, but these words are notthe exclusive means of identifying such statements. Such statementsinclude, but are not limited to, any statements relating to theCompany's drug development program, including, but not limited to thePRECISE trial and other clinical studies involving cintredekinbesudotox, future patient enrollment in the Company's current andplanned clinical trials, including PRECISE, and any other statementsthat are not historical facts. Such statements involve risks anduncertainties, including, but not limited to, those risks anduncertainties relating to difficulties or delays in financing,development, testing, obtaining regulatory approval, production andmarketing of the Company's drug and non-drug compounds, including, butnot limited to, cintredekin besudotox, uncertainty regarding theavailability of third party production capacity, unexpected adverseside effects or inadequate therapeutic efficacy of the Company's drugand non-drug compounds, including, but not limited to, cintredekinbesudotox, that could slow or prevent products coming to market,uncertainty regarding the Company's ability to market its drug andnon-drug products, including, but not limited to, cintredekinbesudotox, the uncertainty of patent protection for the Company'sintellectual property or trade secrets, including, but not limited to,cintredekin besudotox, and other risks detailed from time to time infilings the Company makes with the Securities and Exchange Commissionincluding its annual reports on Form 10-K and quarterly reports onForms 10-Q. Such statements are based on management's currentexpectations, but actual results may differ materially due to variousfactors, including those risks and uncertainties mentioned or referredto in this press release. Accordingly, you should not rely on theseforward-looking statements as a prediction of actual future results.